Suchergebnisse - "Dvorkin, Mikhail"

PubPharm (12)

1

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab : Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2021

von Syrigos, K. | Abert, I. | Andric, Z. | +13

2

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Lee, N. | Ferris, R. | Psyrri, A. | +18

CommentIn: Lancet Oncol. 2021 Jul;22(7):e290. - PMID 34197752

3

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers : Results From JAVELIN Gastric 100

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Moehler, M. | Dvorkin, M. | Boku, N. | +18

4

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Goldman, J. | Dvorkin, M. | Chen, Y. | +123

CommentIn: Lancet Oncol. 2021 Mar;22(3):e83. - PMID 33662291

5

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

enthalten in: The New England journal of medicine | 2020

von Shaw, A. | Bauer, T. | de Marinis, F. | +112

CommentIn: Nat Rev Clin Oncol. 2021 Jan;18(1):6. - PMID 33262501

6

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer : results from TAGS

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2020

von Tabernero, J. | Alsina, M. | Shitara, K. | +18

7

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Paz-Ares, L. | Dvorkin, M. | Chen, Y. | +122

CommentIn: Lancet. 2019 Nov 23;394(10212):1884-1885. - PMID 31590987

8

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer : JAVELIN Gastric 100 study design

enthalten in: Future oncology (London, England) | 2019

von Moehler, M. | Ryu, M. | Dvorkin, M. | +19

9

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS) : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von Shitara, K. | Doi, T. | Dvorkin, M. | +18

CommentIn: Lancet Oncol. 2018 Nov;19(11):1418-1419. - PMID 30355454

10

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses : A Phase 2 Randomized Clinical Trial

enthalten in: JAMA oncology | 2018

von Montagut, C. | Argilés, G. | Ciardiello, F. | +29

ErratumIn: JAMA Oncol. 2019 May 1;5(5):745. - PMID 31070664